A drenal disorders and non-alcoholic fatty liver disease

被引:24
|
作者
Papanastasiou, Labrini [1 ,2 ]
Fountoulakis, Stelios [1 ,2 ]
Vatalas, Ioannis-Anastasios [3 ]
机构
[1] G Gennimatas Gen Hosp, Dept Endocrinol, 154 Mesog Ave, Athens 11527, Greece
[2] G Gennimatas Gen Hosp, Diabet Ctr, 154 Mesog Ave, Athens 11527, Greece
[3] Univ Athens, Med Sch, Unit Translat Med & Clin Res Endocrinol, Athens, Greece
关键词
Adrenal glands; Non-alcoholic fatty liver disease; Glucocorticoids; Aldosterone; Dehydroepiandrosterone; Catecholamines; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; HEPATIC INSULIN SENSITIVITY; RENIN-ANGIOTENSIN SYSTEM; GLUCOCORTICOID-RECEPTOR; METABOLIC SYNDROME; SEVERE STEATOHEPATITIS; ADRENAL INSUFFICIENCY; PREDNISOLONE THERAPY; CORTISOL SECRETION; CIRCULATING LEVELS;
D O I
10.23736/S0391-1977.16.02583-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the developed world and its pathogenesis is complex and multifactorial. It is considered the hepatic manifestation of the metabolic syndrome and is the leading cause of hepatic cirrhosis. This review aims to present current knowledge on the involvement of the adrenal glands in the development of NAFLD. Clinical and animal studies have shown that excess glucocorticoids (GC) have been implicated in the pathogenesis of NAFLD. Patients with NAFLD seem to have a subtle chronic activation of the hypothalamic pituitary adrenal axis leading to a state of subclinical hypercortisolism. Regulators of GC such as 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1), an enzyme that regenerates cortisol from inactive cortisone, and 5a/5 beta-reductases, enzymes that increase cortisol clearance, are implicated in the development of NAFLD by amplifying local GC action. Adrenal androgen (dehydroepiandrosterone) abnormalities and increased aldosterone levels may also have a role in the development of NAFLD whereas the contribution of adrenergic signaling in NAFLD pathogenesis remains unclear.
引用
收藏
页码:151 / 163
页数:13
相关论文
共 50 条
  • [31] Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease
    Polyzos, Stergios A.
    MINERVA ENDOCRINOLOGICA, 2017, 42 (02) : 89 - 91
  • [32] SLEEP DISORDERS IN INDIVIDUALS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Stepanova, M.
    Afendy, M.
    Srishord, M.
    Esceik, C.
    Mishra, A.
    Younossi, Z. M.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S525 - S525
  • [33] Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation
    Burke, A
    Lucey, MR
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (05) : 686 - 693
  • [34] NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC FATTY PANCREAS DISEASE: A NEW INTRIGUING ASSOCIATION?
    Della Corte, Claudia
    Mosca, Antonella
    Sartorelli, Maria Rita
    Comparcola, Donatella
    Liccardo, Daniela
    Alterio, Arianna
    Lucidi, Vincenzina
    Nobili, Valerio
    DIGESTIVE AND LIVER DISEASE, 2014, 46 : E101 - E101
  • [35] NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS RELATED TO NON-ALCOHOLIC FATTY PANCREAS DISEASE (NAFPD)
    van Geenen, Erwin-Jan M.
    Smits, Mark M.
    Schreuder, Tim C.
    Bloemena, Elisabeth
    van der Peet, Donald L.
    Mulder, Chris J.
    HEPATOLOGY, 2009, 50 (04) : 788A - 788A
  • [36] Non-alcoholic fatty liver disease and liver secretome
    Khan, Muhammad Sohaib
    Lee, Choongho
    Kim, Sang Geon
    ARCHIVES OF PHARMACAL RESEARCH, 2022, 45 (12) : 938 - 963
  • [37] Liver transplantation and non-alcoholic fatty liver disease
    Zezos, Petros
    Renner, Eberhard L.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (42) : 15532 - 15538
  • [38] Liver transplantation for non-alcoholic fatty liver disease
    Germani, Giacomo
    Becchetti, Chiara
    MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 2018, 64 (02) : 138 - 146
  • [39] Non-alcoholic fatty liver disease and liver transplantation
    Khan, Reenam S.
    Newsome, Philip N.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (08): : 1208 - 1223
  • [40] Non-alcoholic fatty liver disease and liver secretome
    Muhammad Sohaib Khan
    Choongho Lee
    Sang Geon Kim
    Archives of Pharmacal Research, 2022, 45 : 938 - 963